Cargando…
Medicaid spending on contraceptive coverage and pregnancy-related care
OBJECTIVE: Up to 50% of pregnancies are unintended in the United States, and the healthcare costs associated with pregnancy are the most expensive among hospitalized conditions. The current study aims to assess Medicaid spending on various methods of contraception and on pregnancy care including uni...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946128/ https://www.ncbi.nlm.nih.gov/pubmed/24581033 http://dx.doi.org/10.1186/1742-4755-11-20 |
_version_ | 1782306612042530816 |
---|---|
author | Laliberté, François Lefebvre, Patrick Law, Amy Duh, Mei Sheng Pocoski, Jennifer Lynen, Richard Darney, Philip |
author_facet | Laliberté, François Lefebvre, Patrick Law, Amy Duh, Mei Sheng Pocoski, Jennifer Lynen, Richard Darney, Philip |
author_sort | Laliberté, François |
collection | PubMed |
description | OBJECTIVE: Up to 50% of pregnancies are unintended in the United States, and the healthcare costs associated with pregnancy are the most expensive among hospitalized conditions. The current study aims to assess Medicaid spending on various methods of contraception and on pregnancy care including unintended pregnancies. METHODS: We analyzed Medicaid health claims data from 2004 to 2010. Women 14–49 years of age initiating contraceptive methods and pregnant women were included as separate cohorts. Medicaid spending was summarized using mean all-cause and contraceptive healthcare payments per patient per month (PPPM) over a follow-up period of up to 12 months. Medicaid payments were also estimated in 2008 per female member of childbearing age per month (PFCPM) and per member per month (PMPM). Medicaid payments on unintended pregnancies were also evaluated PFCPM and PMPM in 2008. RESULTS: For short-acting reversible contraception (SARC) users, all-cause payments and contraceptive payments PPPM were respectively $365 and $18.3 for oral contraceptive (OC) users, $308 and $19.9 for transdermal users, $215 and $21.6 for vaginal ring users, and $410 and $8.8 for injectable users. For long-acting reversible contraception (LARC) users (follow-up of 9–10 months), corresponding payments were $194 and $36.8 for IUD users, and $237 and $29.9 for implant users. Pregnancy cohort all-cause mean healthcare payments PPPM were $610. Payments PFCPM and PMPM for contraceptives were $1.44 and $0.54, while corresponding costs of pregnancies were estimated at $39.91 and $14.81, respectively. Payments PFCPM and PMPM for contraceptives represented a small fraction at 6.56% ($1.44/$21.95) and 6.63% ($0.54/$8.15), respectively of the estimated payments for unintended pregnancy. CONCLUSIONS: This study of a large sample of Medicaid beneficiaries demonstrated that, over a follow-up period of 12 months, Medicaid payments for pregnancy were considerably higher than payments for either SARC or LARC users. Healthcare payments for contraceptives represented a small proportion of payments for unintended pregnancy when considering the overall Medicaid population perspective in 2008. |
format | Online Article Text |
id | pubmed-3946128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39461282014-03-09 Medicaid spending on contraceptive coverage and pregnancy-related care Laliberté, François Lefebvre, Patrick Law, Amy Duh, Mei Sheng Pocoski, Jennifer Lynen, Richard Darney, Philip Reprod Health Research OBJECTIVE: Up to 50% of pregnancies are unintended in the United States, and the healthcare costs associated with pregnancy are the most expensive among hospitalized conditions. The current study aims to assess Medicaid spending on various methods of contraception and on pregnancy care including unintended pregnancies. METHODS: We analyzed Medicaid health claims data from 2004 to 2010. Women 14–49 years of age initiating contraceptive methods and pregnant women were included as separate cohorts. Medicaid spending was summarized using mean all-cause and contraceptive healthcare payments per patient per month (PPPM) over a follow-up period of up to 12 months. Medicaid payments were also estimated in 2008 per female member of childbearing age per month (PFCPM) and per member per month (PMPM). Medicaid payments on unintended pregnancies were also evaluated PFCPM and PMPM in 2008. RESULTS: For short-acting reversible contraception (SARC) users, all-cause payments and contraceptive payments PPPM were respectively $365 and $18.3 for oral contraceptive (OC) users, $308 and $19.9 for transdermal users, $215 and $21.6 for vaginal ring users, and $410 and $8.8 for injectable users. For long-acting reversible contraception (LARC) users (follow-up of 9–10 months), corresponding payments were $194 and $36.8 for IUD users, and $237 and $29.9 for implant users. Pregnancy cohort all-cause mean healthcare payments PPPM were $610. Payments PFCPM and PMPM for contraceptives were $1.44 and $0.54, while corresponding costs of pregnancies were estimated at $39.91 and $14.81, respectively. Payments PFCPM and PMPM for contraceptives represented a small fraction at 6.56% ($1.44/$21.95) and 6.63% ($0.54/$8.15), respectively of the estimated payments for unintended pregnancy. CONCLUSIONS: This study of a large sample of Medicaid beneficiaries demonstrated that, over a follow-up period of 12 months, Medicaid payments for pregnancy were considerably higher than payments for either SARC or LARC users. Healthcare payments for contraceptives represented a small proportion of payments for unintended pregnancy when considering the overall Medicaid population perspective in 2008. BioMed Central 2014-03-03 /pmc/articles/PMC3946128/ /pubmed/24581033 http://dx.doi.org/10.1186/1742-4755-11-20 Text en Copyright © 2014 Laliberté et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. |
spellingShingle | Research Laliberté, François Lefebvre, Patrick Law, Amy Duh, Mei Sheng Pocoski, Jennifer Lynen, Richard Darney, Philip Medicaid spending on contraceptive coverage and pregnancy-related care |
title | Medicaid spending on contraceptive coverage and pregnancy-related care |
title_full | Medicaid spending on contraceptive coverage and pregnancy-related care |
title_fullStr | Medicaid spending on contraceptive coverage and pregnancy-related care |
title_full_unstemmed | Medicaid spending on contraceptive coverage and pregnancy-related care |
title_short | Medicaid spending on contraceptive coverage and pregnancy-related care |
title_sort | medicaid spending on contraceptive coverage and pregnancy-related care |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946128/ https://www.ncbi.nlm.nih.gov/pubmed/24581033 http://dx.doi.org/10.1186/1742-4755-11-20 |
work_keys_str_mv | AT lalibertefrancois medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare AT lefebvrepatrick medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare AT lawamy medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare AT duhmeisheng medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare AT pocoskijennifer medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare AT lynenrichard medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare AT darneyphilip medicaidspendingoncontraceptivecoverageandpregnancyrelatedcare |